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Introduction
Apoptosis described by Kerr in 1972 [1], also called pro-
grammed cell death, is one of the most important factors
in the pathogenesis of various liver diseases [2–5]. The
main features of apoptosis include: deletion of single cells,
cell shrinking, and the final formation of apoptotic bod-
ies without inflammatory response and phagocytosis by
adjacent normal cells and some macrophages, as well as
compaction of chromatin into uniformly dense masses.
Apoptosis is present at low rate in the human liver as a
physiological part of liver cell homeostasis and at a higher
rate in several liver diseases. Three proteins with different
activities were found to have major role in apoptosis oc-
curring in the liver: FAS/APO-1 and Bax are located
mainly at the surface of hepatocytes and Bcl-2 is located
on the biliary epithelium and on the lymphocytes [6–11].
In Fas-mediated apoptosis, Fas-L – expressed either on
the cell surface of lymphocytes or intracellularly binds to
Fas in a soluble form that induces apoptosis via the cas-
pase-8 cascade. The multistep process is enhanced by Bax
and inhibited by Bcl-2. TGF-b, which is a regulatory cy-
tokine of the immune response [12] produced by
macrophages, enhances the effect of Bax, while IFN-c
induces apoptosis via the TNF-a and perforin system as
well. CD4 and CD8 positive T-cells also influence the ef-
fect of Bcl-2 [6–10]. Apoptosis was observed in several
different complications following liver transplantation,
such as acute rejection [5, 13, 14]. Since chronic liver re-
jection is characterized by the loss of bile ducts, arteri-
opathy and fibrosis [10, 14–19], at least two different
pathophysiological aspects can be assumed: T-cell medi-
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Abstract: In chronic liver rejection lymphocyte mediated processes lead to chronic inflammation, necrosis and repair mechanisms. The aim of the
present study was to investigate the expression of apoptosis related proteins (FAS/APO-1, FAS-L, Bcl-2, Bax, TNF-a, and INF-c). ApopTag re-
action and immunohistochemistry were performed on liver samples of chronically rejected allografts and compared with normal donor livers. In
chronic rejection, apoptosis was detected in pericentral hepatocytes and in the biliary epithelium. Bcl-2 was strongly expressed on lymphocytes
around the bile ducts, but not on the biliary epithelium itself. Bax, FAS, TNF-a and INF-c were present in pericentral areas. T-cells showed up
around bile ducts, whereas macrophages around pericentral areas. In pericentral areas apoptosis seems to be fostered through TNF-a and INF-c
and by the lack of Bcl-2. Based on these results both downregulation and upregulation of apoptotic proteins can be observed in chronic liver al-
lograft rejection: FAS is upregulated in biliary epithelium and zone 2, protein levels of FASL remain unchanged, BAX is upregulated in zone 3,
BCL2 is downregulated in both biliary epithelium and zone 1 and both TNFa and IFN are upregulated in zone 3. Our results suggest that the
balance between pro- and antiapoptotic patterns was shifted to the proapoptotic side, mainly in the centrilobular area of the hepatic lobule, and
in the bile ducts. According to these findings in chronic rejection the predictive sites of apoptosis are the biliary epithelium and the pericentral areas.
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ated inflammation of the epithelial structures and
parenchymatous scarring promoted by macrophages and
lymphocytes [12]. Our previous study [15, 21] showed
that TGFb-1 – which plays a role in programmed cell
death – is produced in higher rates in chronic allograft
rejection by macrophages compared to TGFb-1 synthe-
sized by normal livers. In order to evaluate both pre-
sumed pathways, we investigated the expression patterns
of three apoptosis proteins (FAS/APO-1, Bax and Bcl-2)
and two cytokines (TNF-a, INF-c) in comparison with
lymphocyte and macrophage distribution, as well as
ApopTag Plus reaction in chronically rejected human
liver allografts.
Materials and Method
Tissue samples
Specimens from explanted liver allografts were obtained
at the time of retransplantation of 10 patients with
chronic rejection proven by histology of previous biopsies
according to the Banff criteria [22]. Transplantations
were performed for primary sclerosing cholangitis in two
cases, for primary biliary cirrhosis in two cases and for
hepatitis B and C in 6 cases. Median of the graft survival
was 5.3 months (min. 3, max. 14) in 9 patient, and 8
years in one patient. Baseline immunosuppression con-
sisted of cyclosporine and low-dose steroid. Acute rejec-
tion episodes were treated with daily bolus of methyl-
prednison, antithymocyte globulin or Azathioprine.
OKT3 was administered in one case of steroid resistant
rejection. Baseline immunosuppression was converted to
FK506 in three patients between weeks 15–30 after the
OLT (orthotopic liver transplantation). Patient demo-
graphics are summarized in Table I. Healthy tissue con-
trols with no morphological abnormalities were obtained
from 8 healthy donor livers. All liver samples were snap-
frozen in liquid nitrogen, then stored in a freezer at –80
°C until used, as well as fixed in 10% buffered formalde-
hyde, and embedded into paraffin.
Antibodies
All primary antibodies used in the study are summarized
in Table II.
Immunohistochemistry
Immunohistochemical studies were performed as de-
scribed earlier [15, 21]. Frozen liver specimens were cut
into 5-µm-thick sections on a cryostat, fixed in acetone
for 10 minutes immediately before use. For immunola-
beling experiments, sections were preincubated with
heat-inactivated human AB serum, diluted 1:10 in phos-
phate-buffered saline (PBS) for 20 minutes to block non-
specific binding and then covered with a layer of the pri-
mary antibody in appropriate dilution for 60 minutes.
After three washes in PBS, the secondary antibody (5%
peroxydase coupled goat anti-mouse immunoglobulin
(Jackson ImmunoResearch Europe Ltd. Soham, Cam-
bridgeshire, UK) and 5% heat-inactivated human serum
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Table I Demographic data of the patients
No Gender Age Disease
Graft survival
(months)
1 Male 17 PSC 3
2 Male 25 PSC 96
3 Female 50 Hepatitis B 14
4 Male 50 Hepatitis C 4
5 Female 53 PBC 8
6 Female 48 Non-A non-B hepatitis 10
7 Male 60 PBC 35
8 Male 38 Hepatitis B+ HCC 3
9 Male 41 Non-A non-B hepatitis 9
10 Female 39 Non-A non-B hepatitis 3
Table II Antibodies used for the recent study
Specificity Clone Source
FAS/APO-1 Mouse, DX-2 DAKO, Denmark
Bcl-2 Mouse, Bcl-2, 124 DAKO, Denmark
Bax Rabbit, N-20b Santa Cruz Biotechnology
CD 3 (T cells) Mouse, Leu-4 Becton Dickinson
CD 4 (T helper and macrophages) Mouse Leu-3a Becton Dickinson
CD 8 (T cytotoxic/suppressor) Mouse, Leu-2a Becton Dickinson
CD 20 (B cells) Mouse, Leu-16 Becton Dickinson
CD 56 (NK cells) Mouse, MY31 Becton Dickinson
25 F9 (macrophages) Mouse, 25F9 Prof. Dr. Sorge, Munster
27E10 (macrophages) Mouse, 27E10 Prof. Dr. Sorge, Munster
TNF-a 6401 Becton Dickinson
INF-c 25723 Becton Dickinson
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in PBS were applied for 60 minutes, followed by further
washing steps in PBS. Binding of the secondary antibody
was detected by incubation with aminoethyl carbazole
(DAKO, Carpinteria, CA, USA) in acetate buffer (pH
5.2) containing hydrogen peroxide or with diaminoben-
zidine (DAKO, Carpinteria, CA, USA) in imidazol-HCL
buffer pH 7.5 containing hydrogen peroxide. After rins-
ing in tap water, the sections were counterstained with
Mayer’s hemalum and mounted in glycergel. For negative
control samples, primary antibody was omitted and re-
placed by PBS or irrelevant antibody.
Immunohistochemistry on paraffin embedded samples:
In order to retrieve antigens after the standard procedures
of formalin fixation, embedding, cutting and deparaf-
finization, tissue sections were treated by microwave in
Antigen Unmasking Solution (Vector Laboratories, Inc.;
Burlingame, CA, USA) for 10 minutes. Primary anti-
bodies used on frozen sections were applied overnight at
4 °C in appropriate dilution on the samples. Further pro-
cessing was the same as for the frozen sections.
Cells undergoing programmed cell death (apoptosis)
were detected by in situ specific labeling of nuclear DNA
fragmentation method (C-terminal deoxynucleotidyl
transferase-mediated dUTP-biotin nick end labeling;
TUNEL method) using ApopTag in situ apoptosis de-
tection kit (Oncor, Gaithersburg, MD, USA). Paraffin-
embedded thin sections (4 µm) were deparaffinised and
digested with 20 µg ml–1 proteinase K (DAKO, Carpin-
teria, CA, USA). Endogenous peroxidase activity was
blocked with the treatment of 2.0% hydrogen peroxide
in phosphate-buffered saline (PBS) for 5 minutes. The
sections were then incubated with working strength TdT
enzyme in a humidified chamber at 37 °C for 1 hour,
rinsed with working strength stop/wash buffer, and in-
cubated with anti-digoxigenin peroxidase for 30 minutes.
Diaminobenzidine (DAKO, Carpinteria, CA, USA) was
applied for visualization. For each sample a negative con-
trol slide was included, which received identical treat-
ment, except that TdT was omitted from the reaction
mixture. Peripheral blood lymphocytes treated with dex-
amethasone were used as a positive control for apoptosis.
TUNEL-positive cells were recognized by means of the
following features: chromatin condensation, fragments of
positively stained chromatin in apoptotic bodies, and pos-
itive staining of single, scattered cells
Semiquantitative evaluation
The samples were analyzed individually by two experi-
enced liver pathologist using brightfield microscopy. Ac-
cording to the commonly used semiquantitative evalua-
tion method [10, 18], immunoreactivity was assessed by
a scale rated from negative (–) to strongly positive (+++),
corresponding to the intensity of staining or relative to
the number of positive stained cells. Positive and negative
control slides were examined after each experiment to
verify the reliability of the immunohistochemical reaction.
Results
Expression of the different apoptosis proteins was ana-
lyzed in three main locations:
1. on the lymphoid infiltrate in the portal tract,
2. on the hepatocytes according to the zonal structure
of the hepatic lobule (zones 1–3) and
3. on the bile duct epithelium.
The results are summarized on Tables III and IV.
Negative control slides did not reveal positive staining in
any case (Figs 6 and 7). Normal livers (Table III): Nor-
mal liver tissue showed very rare ApopTag positivity on
every location, including the biliary epithelium, only
zone 3 (pericentral) showed a scattered positivity. Fur-
Table III Expression patterns of pro- and anti-apoptotic antibodies
and cytokines in normal livers
Bile duct
epithelium
Pericentral
area
Portal
tracts
TUNEL – + –/+
Fas/APO-1 –/+ +/++ +
Bax – – –
Bcl-2 +/++ –/+ +
T cells CD56 (NK) +/++ – –
CD45 –/+ – ++
TNF-a – – –
IFN-c – – –
IL-6 –/+ – +
*Macrophages 25F9 + +
*Monocytes 27E10 –/+ –/+
*TGF-b1 + –
*Demirci et al. [21]
Table IV Expression patterns of pro- and anti-apoptotic antibodies
and cytokines in chronic rejection of human liver allograft
Bile duct
epithelium
Pericentral
area
Portal
tracts
TUNEL ++ ++ +
Fas/APO-1 +++ ++/+++ +++
Bax – + –
Bcl-2 + –/+ ++/+++
T cells CD56 (NK) – – +
CD45 ++/+++ – ++/+++
TNF-a + – –
IFN-c + – –
IL-6 +/++ – ++
*Macrophages 25F9 +++ +
*Monocytes 27E10 ++/+++ ++
*TGF-b1 ++/+++ –/+
*Demirci et al. [21]
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ther FAS and FAS-L expressions were generally low in
the whole hepatic lobule, moderately strong on the lym-
phoid infiltrate around the portal tract and the biliary
epithelium showed negative result (Fig. 6). Bax im-
munostaining was negative, while Bcl-2 was positive on
the biliary epithelium and in zone 3 (Fig. 7). No ex-
pression of TNF-a and IFN-c was noted. In the normal
liver, a scattered occurrence of CD3 and CD8 positive T-
lymphocytes was found mainly in the portal tracts or in
the sinusoidal lumens. Chronic rejection (Table IV): The
ApopTag (TUNEL) reaction was positive on hepatic
cells, particularly in zone 3 (pericentral, Fig. 1) but it
was also moderately strong on the biliary epithelium.
FAS/CD95 expression was remarkably high on hepato-
cytes in all three zones (Fig. 2A and B), particularly
strong on the biliary epithelium (Fig. 2C) and was al-
most negative on the lymphoid infiltrate in the portal
tract around the bile ducts. The expression of Fas-Ligand
and Bax showed similar characteristics: slight increase on
Nemes et al.
Fig. 3. Bcl-2 expression in the perioportal region, mainly around
the bile duct in chronic rejection (×400 magnification). In-
serted picture: CD3 positive lymphocytes around the bile
ducts (×125 magnification)
Fig. 1. ApopTag (TUNEL) positive hepatocytes around the peri-
central area in chronic rejection (×125 magnification). Black
arrows shows the TUNEL positive cells
Fig. 2A. FAS/APO-1/CD95 positive hepatocytes in the pericen-
tral/centrilobular area in chronic rejection (×200 magnifi-
cation)
Fig. 2B. Dense FAS/APO-1 expression in the portal zone, and on
the biliary epithelium (×400 magnification)
Fig. 2C. High magnification of biliary epithelium (×600 magnifica-
tion): extensively high expression (FAS/APO-1)
Interventional Medicine & Applied Science 81 ISSN 2061-1617 © 2010 Akadémiai Kiadó, Budapest
the hepatocytes of zone 3 and negative in all other loca-
tions (Fig. 4A and B). Bcl-2 was strongly expressed on
the infiltrating lymphocytes in the portal tract around the
bile ducts and no expression was noted elsewhere (Fig.
3). In the liver grafts with chronic rejection the
CD3/CD8 lymphocytes formed heavy infiltrates around
the bile ducts and were present in a scattered pattern in
zone 3 (Fig. 3, inserted picture). TNF-a (Fig. 5) and
IFN-c (not shown) were slightly positive on the hepato-
cytes of zone 3. Normal livers are shown in Figs 6 and 7.
Discussion
The incidence of chronic rejection is around 5–12%, still
being a time-dependent major complication affecting
long-term outcome after liver transplantation [7, 10, 23,
24]. The mechanism of chronic rejection is not com-
pletely understood although main pathways have already
been detected and published [15, 17, 19–21, 25–27].
Histopathology of chronic rejection is defined by cen-
trilobular injury with fibrosis, arteriopathy, perivenulitis
and progressive loss of intrahepatic bile ducts (vanishing bile
duct syndrome) [10, 15, 16, 19, 20, 28]. Fibrosis: Earlier
it was demonstrated [15] that livers with chronic rejec-
tion show characteristic fibrosis and strong macrophage
infiltration at the centrilobular area: (zone 3). TGF-b1
was found highly upregulated in zone 3, while TGF-b3
increased in zones 1 and 2. It was concluded that TGF-
b1 acts in the fibrogenesis of chronic liver allograft re-
jection. It was also demonstrated that chronically rejected
livers reveal a remarkably strong expression and accumu-
lation of extracellular matrix proteins, including fi-
bronectin, tenascin, undulin and collagen. Individual in-
tegrins show different expression patterns according to
the extent of fibrosis suggesting that integrins – suppos-
edly the primary mediators of cell-matrix interactions –
might play a central role in the initiation of the fibrotic
process itself [21, 29].
Localization of apoptosis proteins and lymphocyte subsets
Fig. 4. Scattered BAX (Fig. 4A) and FAS-Ligand, (Fig. 4B) reaction in the centrilobular area of hepatocytes (×200 magnification)
Fig. 5. TNF-alpha positive hepatocytes in the pericentral region in
chronic rejection (×200 magnification). Black arrows show
the dense area
Fig. 6. Normal liver showed only weak non-specific FAS/APO-1
positivity in the cytoplasm of hepatocytes around some of
the central veins (main part) and membrane associated
moderate positivity was present in only one or two hepato-
cyte(s) per slide (black arrow, insert). Original magnifica-
tion: ×600
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Arteriopathy
Foam cell arteriopathy or chronic obliterative arteriopa-
thy is frequently found in chronic rejection [18, 19, 23,
30, 31]. We have detected Chlamydia pneumoniae in
chronically rejected livers [18]. The presence of Chlamy-
dia pneumoniae was also reported in arterial lesions of
non-immunocompromised patients, and is known to be
associated with atherosclerosis [32–34].
Intrahepatic bile duct loss
The vanishing of bile ducts is a well-known pathological
entity [4]. Bile duct loss is an acquired process, recog-
nized by partial or total absence of bile ducts in certain
portal tracts. The underlying process could be immuno-
logical, ischemic, infectious, metabolic or toxic [3–5].
The vanishing bile duct syndrome is well known in
chronic liver allograft rejection [19] and related to both
ischemic and immunological effects [3, 10]. Theoretically
both mechanisms could initiate apoptosis [7]. Although
the immuno-mechanism of bile duct destruction is not
yet discovered completely, it seems to be driven by cy-
tokines and apoptosis [10].
Apoptosis of the biliary epithelium
The biliary epithelium’s homeostasis of cell death and
proliferation [35, 36] is mainly balanced by Bcl-2 [9, 10,
36]. Bcl-2 expression of the biliary epithelium is gener-
ally lower in liver allografts compared to cirrhotic livers
and the degree of their apoptosis correlates with the
acute rejection as well [9]. IFN-c was found to be up-
regulated, while IL-6, TGF-b and TNF-a downregu-
lated in chronically rejecting liver grafts by Hayashi el al.
[37]. The Fas/Fas-L system [36], perforin/granzyme B
system [33], TNF-a/TNF-a receptor system [39], ox-
idative stress [40], and the disturbances of Bcl-2 expres-
sion on biliary epithelium might all be an induction for
biliary apoptosis. The mechanism is similar to PBC,
when the proliferation that counteracts the apoptotic loss
of biliary epithelium is insufficient. This process is slow
and variable in PBC and rapid in allograft rejection. It is
a matter of dispute whether there is a substantial apop-
tosis in the biliary epithelium in ductopenic chronic re-
jection [8, 10].
The expression of TIAF-1 (TGF-b1 induced anti-
apoptotic factor) in the infiltrating T-cells in chronically
rejecting kidney and liver samples is high. This might
prevent the lymphocytes from apoptosis, concluding to
persistent immunoresponse, which results in chronic re-
jection [39]. This is in accordance with the dense infil-
trate of CD3+/CD8+ cells around the bile ducts with
high Bcl-2 expression on lymphocytes observed in our
present study and also described by others [37]. The
similarities in the proinflammatory/immunoregulatory
cytokine and apoptotic profile between acute and
chronic rejection suggest that prolonged acute rejection
could also be a pathogenetic factor for late chronic re-
jection. This is also in agreement with certain
histopathological [42, 43] and clinical findings [23, 44].
Zou et al. did not find differences in Fas expression pat-
terns between normal and fatty livers as well as NASH
livers [45]. In our present study we focused on the
apoptotic balance of chronic liver rejection. According
to our assumption the expression pattern of pro- and
anti-apoptotic factors is different in the hepatic lobule
and on the biliary epithelium. Correspondingly, allo-
grafts with chronic rejection showed increased rate of
apoptosis, particularly in the centrilobular (zone 3) areas
and on the bile duct epithelium compared to normal liv-
ers. Corresponding with the high apoptotic rate, signif-
icant FAS/APO-1 expression was found equally in all
zones (Fig. 2), but as other parts of the proapoptotic
pathways, Fas-L and Bax were expressed in centrilobu-
lar location (Fig. 4). Macrophages accumulated in cen-
trilobular areas (Fig. 5), TNF-a and IFN-c, known as
macrophage products were also expressed at the same
location. These expression patterns of the proapoptotic
factors explain the centrilobular location of apoptosis of
the hepatocytes. On the contrary, apoptosis-protective
Bcl-2 was mostly detected on lymphocytes surrounding
the bile ducts (Fig. 3), therefore these were free to act
and destroy bile ducts in all cases of chronic rejection.
The infiltrating lymphocytes markedly expressed
CD3/CD8, as described earlier [15, 21]. While in the
pericentral area the process seems to be fostered
through TGF-b [13], TNF-a and IFN-c produced by
the macrophages and also enhanced by the upregulation
of Fas/Fas-L and Bax, the mechanism of apoptosis in
the biliary epithelium seems to be based on the down-
regulation of the protective Bcl-2 and the activation of
the Fas/Fas-L system. Our findings support the results
Nemes et al.
Fig. 7. The normal liver showed positivity for bcl-2 only in normal
portal lymphocytes (black arrows) which served as internal
positive control for the reaction. Original magnification:
×600
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of Koukoulis et al. [10], and correlate with standard
histopathology as well [22].
Our results suggest that the balance between pro- and
antiapoptotic patterns was shifted to the proapoptotic
side, mainly in the centrilobular area of the hepatic lob-
ule, and on bile ducts. In conclusion it seems that in
chronic rejection both downregulation and upregulation
of apoptotic proteins can be observed: FAS is upregu-
lated in biliary epithel and zone 2, proteinlevels of FASL
remain unchanged, BAX is upregulated in zone 3, BCL2
is downregulated in both biliary epithel and zone 1 and
both TNFa and IFN are upregulated in zone 3. Accord-
ing to these findings in chronic rejection the predictive
sites of apoptosis are the biliary epithelium and the peri-
central areas.
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